Country

Font Size

Cytovation and Cancer Research UK Collaborate on Phase 2 Trial for Adrenocortical Carcinoma Treatment

News Image for Cytovation and Cancer Research UK Collaborate on Phase 2 Trial for Adrenocortical Carcinoma Treatment
AI-Generated Summary

Cancer Research UK has partnered with Cytovation and the Norwegian Cancer Society to conduct a Phase 2 clinical trial for the treatment of adrenocortical carcinoma using the new immunotherapy CY-101.

The Norwegian Cancer Society to provide co-funding to support the trial

LONDON, UK, and BERGEN and OSLO, Norway, 23 January 2025 - Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation's lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC).

This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies.

CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer cells, triggering a systemic immune response, while simultaneously inhibiting the Wnt/β-catenin signalling pathway, a key driver of immunotherapy resistance in cancers such as ACC.

CY-101's development builds on compelling data from Cytovation's Phase 1 CICILIA trial, which demonstrated encouraging outcomes in patients with solid tumours. Notably, two ACC patients had clear clinical benefit, with one achieving 18 months of progression-free survival and continuing treatment on a named-patient basis. These results highlight CY-101's potential to address the specific mechanisms of ACC.

A collaborative approach

Under the agreement, Cancer Research UK's Centre for Drug Development (CDD) will sponsor, design and deliver the Phase 2 trial and Cytovation will be responsible for providing CY-101 for the clinical trial. Cancer Research Horizons, Cancer Research UK's innovation arm, will manage the commercial relationship between the three parties.

The Norwegian Cancer Society's support provides access to the additional resources, patients and sites required for trials in rare diseases. Due to the rarity of ACC, the clinical trial will run across multiple sites in the UK and Europe, to ensure robust patient recruitment.

Lars Erwig, Director of the Centre for Drug Development, Cancer Research UK, said: "This collaboration represents a critical step toward addressing the needs of ACC patients who currently have very few treatment options. Cytovation has made impressive progress with CY-101 so far and we are excited to build on our existing partnership with the Norwegian Cancer Society to take its development further."

Lars Prestegarden, CEO, Cytovation, said: "We are very excited about this partnership, proud to follow in the footsteps of groundbreaking agents that Cancer Research UK has contributed to developing, and honoured by the Norwegian Cancer Society's support. We believe CY-101 has the potential to be transformational for the treatment of ACC and other cancer types and are eager to bring this innovation to patients."

Ingrid Stenstadvold Ross, CEO of the Norwegian Cancer Society, said: "The partnership with Cancer Research UK's Centre for Drug Development marks a milestone for the Norwegian Cancer Society, enabling us to advance the development of groundbreaking cancer treatments. We are thrilled that our first joint project is a Norwegian innovation, focused on patients with a rare cancer and a substantial unmet need. Together with Cancer Research UK's Centre for Drug Development and Cytovation, we are bringing new hope to patients while highlighting Norwegian research on the international stage."

About Cancer Research UK's Centre for Drug Development

Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years, taking over 160 potential new anti-cancer agents into clinical trials in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase 3 trials. Thirteen agents remain in active development with the potential to reach the market. It currently has a portfolio of 16 projects in preclinical development, Phase 1 or early Phase 2 clinical trials.

About Cytovation

Cytovation ASA is a clinical stage biotech company focused on the development of CY-101, a first-in-class bifunctional immunotherapy.

About the Norwegian Cancer Society

The Norwegian Cancer Society (NCS) is one of the largest organisations in Norway. It represents the voices of those affected by cancer. We have 128,000 members, 27,000 volunteers and 190 employees. All are dedicated to promoting cancer cause. NCS works continuously to improve society's attitude to the prevention and treatment of cancer. We fight cancer locally, nationally and globally. Through research and preventive measures, information, support, advice and lobbying. The Norwegian Cancer Society's purpose is to work to prevent and fight cancer. And to improve quality of life for patients and their families. Our vision is a life without cancer.

Explore More

Trump Administration Highlights ICE Immigration Arrests

Trump Administration Highlights ICE Immigration Arrests

2025-01-28 07:20 PM ET - Fox News

Trump Administration Sees Key Republican Primaries in Florida

Trump Administration Sees Key Republican Primaries in Florida

2025-01-28 07:22 PM ET - Fox News

West Virginia Detains Suspected Illegal Immigrants Following Immigration Cooperation Order

West Virginia Detains Suspected Illegal Immigrants Following Immigration Cooperation Order

2025-01-28 08:17 PM ET - Fox News

Stephen Miller Defends Trump Administration's Federal Aid Actions Against Media Criticism

Stephen Miller Defends Trump Administration's Federal Aid Actions Against Media Criticism

2025-01-28 09:17 PM ET - Fox News

Griner Signs with Atlanta in Historic Free Agency Move

Griner Signs with Atlanta in Historic Free Agency Move

2025-01-28 08:38 PM ET - ESPN.com

Lay's Potato Chips Recall Highlights Allergen Risks and Consumer Trust Issues

Lay's Potato Chips Recall Highlights Allergen Risks and Consumer Trust Issues

2025-01-28 07:16 PM ET - Forbes

Detroit Lions Face Tough Offseason Decisions on Player Cuts

Detroit Lions Face Tough Offseason Decisions on Player Cuts

2025-01-28 07:10 PM ET - Heavy

Linda Lavin Dies at 87 After Lung Cancer Diagnosis

Linda Lavin Dies at 87 After Lung Cancer Diagnosis

2025-01-28 07:37 PM ET - Fox News

iPhone SE to Feature Notch in 2025 Update with Cost Implications and Design Changes

iPhone SE to Feature Notch in 2025 Update with Cost Implications and Design Changes

2025-01-28 07:49 PM ET - Forbes

Manchester Clubs Explore Transfer Opportunities as Players Eye Moves

Manchester Clubs Explore Transfer Opportunities as Players Eye Moves

2025-01-28 07:33 PM ET - ESPN.com

Family Day at Legoland California with Toddler

Family Day at Legoland California with Toddler

2025-01-28 08:15 PM ET - Forbes

Water Main Break Closes Lanes on Spring Garden Street in Greensboro

Water Main Break Closes Lanes on Spring Garden Street in Greensboro

2025-01-28 07:25 PM ET - myfox8.com

City View Apartments Fire Alarm Inspection Nears Deadline

City View Apartments Fire Alarm Inspection Nears Deadline

2025-01-28 07:25 PM ET - KETV

UN Peacekeeping Force Warns of Ethnic Tensions in Eastern Congo

UN Peacekeeping Force Warns of Ethnic Tensions in Eastern Congo

2025-01-28 07:25 PM ET - Watauga Democrat

Medicaid Expansion Bill Fails to Gain Support in Montana Legislature

Medicaid Expansion Bill Fails to Gain Support in Montana Legislature

2025-01-28 08:24 PM ET - missoulian.com

Wolf Man offers a psychological twist on the classic monster story

Wolf Man offers a psychological twist on the classic monster story

2025-01-28 08:24 PM ET - Forbes

Janelle Brown Defends Against Kody Brown's Financial Accusations

Janelle Brown Defends Against Kody Brown's Financial Accusations

2025-01-28 07:37 PM ET - Showbiz Cheat Sheet

Coinbase Launches Operations in Argentina Following Regulatory Approval

Coinbase Launches Operations in Argentina Following Regulatory Approval

2025-01-28 07:36 PM ET - PYMNTS.com

Gerard R Colcords Peninsula Estate Goes on Market After 32 Years

Gerard R Colcords Peninsula Estate Goes on Market After 32 Years

2025-01-28 07:35 PM ET - Easy Reader News

DHS Secretary Kristi Noem Addresses Staff and Immigration Policies

DHS Secretary Kristi Noem Addresses Staff and Immigration Policies

2025-01-28 07:36 PM ET - NTD

Kim Kardashian Shatters Windshield in TV Series Scene

Kim Kardashian Shatters Windshield in TV Series Scene

2025-01-28 07:36 PM ET - TMZ

U.S. Border Patrol Agents Engaged in Gunfight with Suspected Cartel Members

U.S. Border Patrol Agents Engaged in Gunfight with Suspected Cartel Members

2025-01-27 09:10 PM ET - One America News Network